Company Overview and News

3
CRSP / CRISPR Therapeutics AG 8-K (Current Report)

6h sec.gov - 3
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
CRSP

 
CRSP / CRISPR Therapeutics AG 424B5 (Prospectus)

7h sec.gov
424B5 Table of Contents CALCULATION OF REGISTRATION FEE
CRSP

 
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

2018-09-21 globenewswire
ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,210,526 common shares at a public offering price of $47.50 per share, before underwriting discounts. In addition, underwriters have a 30-day option to purchase up to an additional 631,578 common shares at the public offering price less the underwriting discount.
CRSP BR

 
After-hours buzz: TLRY, RHT & more

2018-09-19 cnbc
Tilray stock fell as much as 16 percent in after-hours trading, following a volatile trading day for the Canadian cannabis company. Shares closed up 38 percent, its best day ever as a public company, after surging as much as 90 percent during the day. The stock was halted five times by the Nasdaq for volatility.
MLHR CRSP RHT

 
CRSP / CRISPR Therapeutics AG 424B5 (Prospectus)

2018-09-19 sec.gov
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-227427 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and
CRSP

 
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

2018-09-19 globenewswire
ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $200,000,000 of its common shares. In addition, the underwriters will have a 30-day option to purchase up to $30,000,000 of additional common shares at the public offering price less the underwriting discount.
CRSP BR

 
CRSP / CRISPR Therapeutics AG S-3ASR

2018-09-19 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on September 19, 2018 Registration No. 333-
CRSP

 
CRISPR Therapeutics Partners Up to Take on Diabetes

2018-09-17 247wallst
CRISPR Therapeutics A.G. (NASDAQ: CRSP) shares dipped on Monday after the company announced a collaboration with ViaCyte focused on the discovery, development and commercialization of gene-edited allogeneic stem cell therapies for the treatment of diabetes.
CRSP

 
CRISPR Therapeutics and ViaCyte Collaborate to Tackle Type 1 Diabetes

2018-09-17 biospace
CRISPR Therapeutics and ViaCyte are collaborating to discover, develop and commercialize a gene-edited allogeneic stem cell therapy or therapies for diabetes.
CRSP

9
CRSP / CRISPR Therapeutics AG 8-K (Current Report)

2018-09-17 sec.gov - 9
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
CRSP

1
Crispr Therapeutics Tries Its Hand At β-Thalassemia With Vertex

2018-09-13 seekingalpha - 1
CRISPR Therapeutics has teamed up with Vertex Pharmaceuticals on the first human trial for a CRISPR gene-editing system.
VRTX CRSP

8
Broad Institute Fends off CRISPR Patent Lawsuit, at Least for Now

2018-09-11 biospace - 2
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
NTLA EDIT CRSP

8
CRSP / CRISPR Therapeutics AG 8-K (Current Report)

2018-09-11 sec.gov - 8
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
CRSP

4
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

2018-09-10 globenewswire
ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Caribou Biosciences, Inc. announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) affirmed the decision by the U.S. Patent and Trademark Office’s (“USPTO”) Patent Trial and Appeal Board (“PTAB”) in an interference proceeding relating to CRISPR/Cas9 genome editing technology.
NTLA VRTX CRSP

7
Long-Term Outlook For Crispr Therapeutics: Sept. 5, 2018

2018-09-06 seekingalpha - 1
A June report wiped away some price increases from early 2018; and there's a long-term bullish news with new trials expected to start this year.
NTLA EDIT CRSP

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: H17182108